Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter
Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to $340 million and Non-GAAP adjusted operating expense guidance of $380 to $410 million
Updates to the Ocaliva U.S. Prescribing Information complete
Company provides regulatory update on NASH fibrosis program in the U.S.
Company to host conference call today at 8:30 a.m. ET
Conference Call on July 29, 2021 at 8:30 a.m. ET
We are hosting our second quarter 2021 financial results conference call and webcast on July 29, 2021 at 8:30 a.m. ET. The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 2919379. A replay of the call will be available on our website shortly following the completion of the call and will be available for two weeks.
https://finance.yahoo.com/news/intercept-pharmaceuticals-reports-second-quarter-110000571.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.